A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma
A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma
复制标题
DOI：
10.1038/s41598-020-63200-7
复制
发表时间：
2020-04-10
影响因子：
4.6
通讯作者：
Yamaguchi, Shigeo
中科院分区：
文献类型：
--
作者：
Takakuwa, Kazuya;Mogushi, Kaoru;Yamaguchi, Shigeo
已经报道了许多癌细胞增殖的驱动途径。驱动途径激活通常基于单个热点突变（如EGFR L 858 R）进行评估。然而，由于复杂的肿瘤内网络，驱动途径的影响不能仅基于单个基因突变来预测。在这里，我们开发了一种新的诊断系统命名为“EGFR影响评分”，这是基于多重mRNA表达谱，它可以预测肺癌细胞中的EGFR通路的影响和EGFR-酪氨酸激酶抑制剂对恶性肿瘤的影响。EGFR影响评分表明对早期肺癌预后的稳健预测能力，因为该评分可以评估EGFR途径对肿瘤和基因组不稳定性的影响。此外，预后不良组的分子特征与免疫检查点抑制剂相关的生物标志物相似。EGFR影响评分是一种新的肺腺癌预后和治疗指标。
Many driver pathways for cancer cell proliferation have been reported. Driver pathway activation is often evaluated based on a single hotspot mutation such as EGFR L858R. However, because of complex intratumoral networks, the impact of a driver pathway cannot be predicted based on only a single gene mutation. Here, we developed a novel diagnostic system named the "EGFR impact score" which is based on multiplex mRNA expression profiles, which can predict the impact of the EGFR pathway in lung cancer cells and the effect of EGFR-tyrosine kinase inhibitors on malignancy. The EGFR impact score indicated robust predictive power for the prognosis of early-stage lung cancer because this score can evaluate the impact of the EGFR pathway on the tumor and genomic instability. Additionally, the molecular features of the poor prognostic group resembled those of biomarkers associated with immune checkpoint inhibitors. The EGFR impact score is a novel prognostic and therapeutic indicator for lung adenocarcinoma.